Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
New Strong Buy Stocks for December 16th
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Vertex Pharmaceuticals Incorporated VRTX: This company that engages in developing and commercializing therapies for treating cystic fibrosis has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.8% over the last 60 days.
Vertex Pharmaceuticals Incorporated Price and Consensus
Vertex Pharmaceuticals Incorporated price-consensus-chart | Vertex Pharmaceuticals Incorporated Quote
Gaming and Leisure Properties, Inc. GLPI: This company that is engaged in the business of acquiring, financing, and owning real estate property has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.
Gaming and Leisure Properties, Inc. Price and Consensus
Gaming and Leisure Properties, Inc. price-consensus-chart | Gaming and Leisure Properties, Inc. Quote
The Charles Schwab Corporation SCHW: This company that provides wealth management, securities brokerage, banking, asset management, custody, and financial advisory services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days.
The Charles Schwab Corporation Price and Consensus
The Charles Schwab Corporation price-consensus-chart | The Charles Schwab Corporation Quote
Zynerba Pharmaceuticals, Inc. (ZYNE - Free Report) : This clinical stage specialty pharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.7% over the last 60 days.
Zynerba Pharmaceuticals, Inc. Price and Consensus
Zynerba Pharmaceuticals, Inc. price-consensus-chart | Zynerba Pharmaceuticals, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
See their latest picks free >>